|12/12/18||Adaptimmune Announces that Gwen Binder will leave in January 2019|
|PHILADELPHIA and OXFORD, United Kingdom, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Adaptimmune (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that Gwen Binder, PhD, Chief Technology Officer, will be leaving the company at the end of January 2019.
Dr. Binder was the first US employee of Adaptimmune in 2011, transitioning across from the company’s T-cell translational development collaboration program with the University of Pennsylvania. She led much of the early clinical... |
|11/06/18||Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update|
|Progressed to expansion phase for MAGE-A10 triple tumor and MAGE-A4 basket studies after favorable safety review of Cohort 3 data with target doses of 5 billion cells
Continued dosing in Cohort 1 of AFP study, with anticipated dose escalation to Cohort 2 early 2019
~$26 million upon completion of transition of NY-ESO SPEAR T-cell program IND to GSK
Closed registered direct offering with net proceeds of ~$100 million; guidance updated,
funded to late 2020
Conference call to be held toda... |
|10/25/18||Adaptimmune to Report Third Quarter 2018 Financial Results and Business Update on Tuesday, November 6, 2018|
|PHILADELPHIA and OXFORD, United Kingdom, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the Third Quarter 2018 and provide a general business update before the U.S. markets open on Tuesday, November 6, 2018. Following the announcement, the company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. GMT) on the same day.
The press release and the live webcast of ... |
|10/20/18||Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress|
|PHILADELPHIA and OXFORD, United Kingdom, Oct. 20, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, presented initial data from the first two cohorts of its ongoing studies with its MAGE-A10 and MAGE-A4 SPEAR T-cells in two poster presentations earlier today at the European Society for Medical Oncology (ESMO) Congress in Munich, Germany.
“We are encouraged by the safety data from these initial cohorts, which inc... |